CONTINUE TO SITE
OR WAIT 15 SECS
Aicuris Anti-infective Cures AG has entered into a definitive agreement under which Japan's Asahi Kasei,
AstraZeneca has announced $15 billion investment in China through 2030 to expand medicines manufacturing and R
China-based Simcere Pharmaceutical Group and Germany-headquartered Boehringer Ingelheim have announced a licen
China-based Frontier Biotechnologies Inc. has entered into an exclusive licensing agreement with GSK, a g
Saisei Ventures, a pioneering investment firm focused on advancing Japanese biotechnology and therapeutic inno
South Korea-based SK bioscience has announced that it is advancing the development of a Zaire ebolavirus vacci
Australia-based medtech innovator OncoRes Medical has secured $27 million in private funding, which will help
South Korea-based startup Sky Labs Inc. has entered into an exclusive distribution agreement with Otsuka
Fujifilm Biotechnologies, a world leading contract development and manufacturing organisation (CDMO) for biolo
WuXi Biologics, a global leading Contract Research, Development and Manufacturing Organization (CRDMO), and Ha
APAC Accelerates CERVICAL CANCER Elimination
Cervical cancer remains one of the most pressing women’s health challenges in the Asia Pacific region, accounting for approximately 58 per cent of global deaths, according to an Economist Impact analysis commissioned by the Asia Pacific Women’s Cancer Coalition and supported by Roche. Despite being largely preventable through vaccination and early detection, the disease continues to impose a substantial clinical, social, and economic burden across low, middle, and high income countries in the region. The World Health Organisation has therefore set a target to eliminate cervical cancer as a public health problem by 2030, defined as reducing incidence to fewer than 4 cases per 100,000 women. Achieving this goal requires meeting the 90 70 90 targets by 2030: 90 per cent of girls fully vaccinated against HPV by age 15, 70 per cent of women screened with a high performance test by ages 35 and 45, and 90 per cent of women with precancer or invasive cancer receiving appropriate treatment.
For Feedback, please email us at: communications@mmactiv.com
Dubai International Pharmaceutical & Technology Conference& Exhibition (DUPHAT)
Index Conferences & Exhibitions
info@duphat.ae https://duphat.ae/Dubai World Trade Center
ArabLab 2026 Dubai
Terrapinn Middle East Fz Llc
anne.deguzman@terrapinn.com https://www.terrapinn.com/exhibition/arablab-live/index.stmDubai World Trade Centre, Dubai
ArabLab 2026 Dubai
Terrapinn Middle East Fz Llc
anne.deguzman@terrapinn.com https://www.terrapinn.com/exhibition/arablab-live/index.stmDubai World Trade Centre, Dubai
